2nd TRP Target Selection & Drug Design Summit, Feb 21-24, 2026 in Boston, US
[…]
Fighting Cancer with Precision
Powered by the PreTarg-it® Platform
Next-generation pretargeted radioimmunotherapy designed to deliver radiation with greater control and tumor selectivity.
Structured for Precision. Built for Translation.
Targeted Radionuclide Therapies hold strong potential in oncology but are often limited by off-target radiation exposure.
PreTarg-it® uses a two-step pretargeting strategy separating tumor targeting from radionuclide delivery.
Step 1 – Targeting Phase
A tumor-targeting bispecific antibody
binds to cancer cells
and clears from
the circulation.
Step 2 – Delivery Phase
A radiolabeled molecule binds to the tumor-bound antibody and delivers radiation directly to the tumor while minimizing off-target exposure
This sequential approach enables more controlled radiation delivery, improved tumor selectivity, and enhanced therapeutic precision.
Target First. Treat Precisely.
PreTarg-it® is a modular pretargeted radioimmunotherapy platform that separates tumor targeting from radionuclide delivery to improve therapeutic precision.
Designed for a high therapeutic index and rapid pharmacokinetics without clearing agents, the platform enables flexible pairing of antibody targets and radiolabeled payloads across multiple oncology indications.
OncoOne collaborates with strategic partners to advance defined antibody targets and co-develop novel radioimmunotherapy programs within the PreTarg-it® framework.
Why PreTarg-it® ?
Sequential Targeting
Two-step strategy separating tumor targeting from radionuclide delivery
Strategic Partnerships
Partner in the Next Generation of Radioimmunotherapies
OncoOne is building strategic partnerships to advance oncology programs based on the PreTarg-it® platform.
| Public Grants
